ERF for short term PM10 exposure and medication usage by people with asthma

This page is a knowledge crystal of subtype variable. The page identifier is Op_en3443
Moderator:Virpi Kollanus (see all)
Upload data {{#opasnet_base_link:Op_en3443}}

Scope

Exposure-response function for short-term (acute) exposure to ambient air particulate matter (PM) with an aerodynamic diameter < 10 µm and medication (bronchodilator) usage by people with asthma.

Dimensions and boundaries relevant for the variable

• Age of exposed population
• Country/other geographic area

Definition

Data

WHO task group (2004)

• RR of 1.005 (95% Cl 0.981, 1.029) for bronchodilator usage by children with asthma (meeting PEACE study criteria) per 10 µg/m³ PM₁₀
• RR of 1.010 (95% Cl 0.990, 1.031) for bronchodilator usage by adults with asthma (well-established) per 10 µg/m³ PM₁₀

Note! the associations are not statistically significant at the usual 5% level.

CAFE CBA (2005)

• Annual change of 180 (95% Cl -690, 1060) days in brochodilator usage per 10 µg/m³ PM₁₀ per 1000 children aged 5-14 years with asthma (meeting PEACE study criteria)
  • Based on the RR by WHO task group (2004) and 10% background prevalence of daily bronchodilator use
• Annual change of 912 (95% Cl -912, 2774) days in brochodilator usage per 10 µg/m³ PM₁₀ per 1000 adults aged 20+ with well-established asthma with asthma (well-established)
  • Based on the RR by WHO task group (2004) and 50% background prevalence of daily bronchodilator use
  • 4.5% of European adult population was estimated to have well-established asthma

Unit

Annual change in no. of days of bronchodilator usage per 10 µg/m3 increase in exposure per 1000 persons

Result

Age group	Days	95% Cl
5-14	180	-690, 1060
20+	912	-912, 2774

|}

See also

• NEEDS - New Energy Externalities Developments for Sustainability, Deliverable 3.7 "A set of concentration-response function", Integrated Project, Sixth Framework Programme, Project no. 502687.